Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions
Open Access
- 1 January 2024
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 15
Abstract
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue to drive innovation, and emerging options have the potential to realize further improvement. We advocate four general principles to optimize benefits from innovation: individualizing the treatment approach, targeting ‘normal,’ making the most of available resources, and considering treatment affordability. Ultimately, all PwH—men and women, of all ages and severities, and worldwide—should have access to treatment that fully prevents bleeding, while allowing personal, social, family, and professional lives of choice. Clearly, we are not there yet, but developing goals/milestones based on the principles we describe may help to achieve this.Keywords
Funding Information
- Swedish Orphan Biovitrum
This publication has 34 references indexed in Scilit:
- “Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets”: commentJournal of Thrombosis and Haemostasis, 2023
- Concizumab: First ApprovalDrugs, 2023
- Time to revisit the classification of hemophilia: if it ain’t broke, don’t fix it!Journal of Thrombosis and Haemostasis, 2023
- Reclassifying hemophilia to include the definition of outcomes and phenotype as new targetsJournal of Thrombosis and Haemostasis, 2023
- Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory CoastResearch and Practice in Thrombosis and Haemostasis, 2023
- Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyThe Lancet Haematology, 2023
- Optimising prophylaxis in haemophilia A: The ups and downs of treatmentBlood Reviews, 2021
- Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health DataPharmacoEconomics - Open, 2019
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Definitions in HemophiliaThrombosis and Haemostasis, 2001